AZD 6244: all 119 studies that test it
Page 1 of 2. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.
- Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2)Not yet recruitingNCT07713745Phase 2
- Selumetinib for NF2-Related SchwannomatosisNot yet recruitingNCT07707947Phase 2
- Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal AdenocarcinomaRecruitingNCT07619521Phase 1/2
- Low-dose Selumetinib for the Treatment of Plexiform Neurofibromas in Chinese ChildrenNot yet recruitingNCT06763315Phase 2
- Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNSTRecruitingNCT06735820Phase 1/2
- The Clinical Study of the Treatment of Patients With Type I Neurofibromatosis With Smetinib Hydrosulfate CapsuleNot yet recruitingNCT06621082Phase 2
- Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate CapsuleNot yet recruitingNCT06620354Phase 2
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingNCT06502171Phase 1
- Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1RecruitingNCT06188741Phase 2
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaRecruitingNCT04166409Phase 3
- Selumetinib and Azacitidine in High Risk Chronic Blood CancersRecruitingNCT03326310Phase 1
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingNCT02813135Phase 1/2
- Efficacy and Safety of Selumetinib in Adults With NF1 Who Have Symptomatic, Inoperable Plexiform NeurofibromasActive, not recruitingNCT04924608Phase 3Results posted
- Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors (MK-5618-001)TerminatedNCT03833427Phase 1Results posted
- AMTEC IIT: Phase 2 Multiarm Study in TNBCTerminatedNCT03801369Phase 2Results posted
- Study of MK-8353 + Selumetinib in Advanced/Metastatic Solid Tumors (MK-8353-014)CompletedNCT03745989Phase 1Results posted
- Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerCompletedNCT03581487Phase 1/2Results posted
- SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath TumorsCompletedNCT03433183Phase 2Results posted
- Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213691Phase 2Results posted
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
- Trial of Selumetinib in Patients With Neurofibromatosis Type II Related TumorsTerminatedNCT03095248Phase 2Results posted
- Selumetinib Sulfate in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12R MutationsCompletedNCT03040986Phase 2Results posted
- Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous NeurofibromaCompletedNCT02839720Phase 2Results posted
- Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid CancerCompletedNCT02393690Phase 2Results posted
- Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLCCompletedNCT02337530Phase 2Results posted
- A Study to Assess the Relative Bioavailability of Process Variants of Selumetinib in Healthy Male VolunteersCompletedNCT02322749Phase 1Results posted
- A Study to Assess the Absolute Bioavailability of Oral Selumetinib in Healthy Male Volunteers.CompletedNCT02238782Phase 1Results posted
- Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung CancerCompletedNCT02179671Phase 2Results posted
- To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Patients With Hepatic Impairment and Healthy SubjectsCompletedNCT02063230Phase 1Results posted
- To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male VolunteersCompletedNCT02056392Phase 1Results posted
- Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)CompletedNCT01974752Phase 3Results posted
- Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 StudyTerminatedNCT01949870Phase 1Results posted
- Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLCActive, not recruitingNCT01933932Phase 3Results posted
- Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid CancerTerminatedNCT01843062Phase 3Results posted
- Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung CancerCompletedNCT01809210Phase 1Results posted
- Assess Efficacy and Safety of AZD6244 in Combination With Docetaxel in Patients Receiving Second Line Non Small Cell Lung Cancer Treatment.CompletedNCT01750281Phase 2Results posted
- Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With ChemotherapyCompletedNCT01658943Phase 2Results posted
- Investigate the Safety and Tolerability of AZD6244 Monotherapy or + Docetaxel in Japanese Patients With Advanced Solid Malignancies or Non-Small Cell Lung CancerCompletedNCT01605916Phase 1Results posted
- A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)CompletedNCT01586624Phase 1Results posted
- Selumetinib and Akt Inhibitor MK2206 in Treating Patients With Stage III or Stage IV Melanoma Who Failed Prior Therapy With Vemurafenib or DabrafenibTerminatedNCT01519427Phase 2Results posted
- MK-2206 and AZD6244 in Patients With Advanced Colorectal CarcinomaCompletedNCT01333475Phase 2Results posted
- Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast CancerCompletedNCT01313039Early Phase 1Results posted
- Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedNCT01306045Phase 2Results posted
- Selumetinib in Treating Patients With Relapsed or Refractory Diffuse Large B-cell LymphomaTerminatedNCT01278615Phase 2Results posted
- Docetaxel With or Without AZD6244 in MelanomaCompletedNCT01256359Phase 2Results posted
- BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung CancerCompletedNCT01248247Phase 2Results posted
- Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...CompletedNCT01229150Phase 2Results posted
- Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerCompletedNCT01222689Phase 2Results posted
- Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IVTerminatedNCT01166126Phase 2Results posted
- Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the EyeCompletedNCT01143402Phase 2Results posted
- A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the RectumTerminatedNCT01134601Phase 1Results posted
- AZD6244 (Selumetinib) in Treating Patients With Multiple MyelomaCompletedNCT01085214Phase 2Results posted
- A Combination Therapy Study of MK-2206 and AZD6244 in Participants With Advanced Solid Tumors (MK-2206-010)CompletedNCT01021748Phase 1Results posted
- Selumetinib in Treating Patients With Recurrent or Persistent Endometrial CancerCompletedNCT01011933Phase 2Results posted
- Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244CompletedNCT00970359Not applicableResults posted
- Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma PatientsCompletedNCT00936221Phase 2Results posted
- AZD6244 in Combination With Docetaxel Versus Docetaxel Alone in KRAS Mutation Positive NSCLC PatientsCompletedNCT00890825Phase 2Results posted
- Selumetinib in Cancers With BRAF MutationsCompletedNCT00888134Phase 2Results posted
- MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV MelanomaCompletedNCT00866177Phase 2Results posted
- Personalized Treatment Selection for Metastatic Breast CancerTerminatedNCT00780676Phase 2Results posted
- Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver CancerCompletedNCT00604721Phase 2Results posted
- Selumetinib in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00588809Phase 2Results posted
- Selumetinib in Treating Patients With Papillary Thyroid Cancer That Did Not Respond to Radioactive IodineCompletedNCT00559949Phase 2Results posted
- Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By SurgeryCompletedNCT00553332Phase 2Results posted
- Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum CancerCompletedNCT00551070Phase 2Results posted
- Selumetinib in Chinese Paediatric With Post-operative NF1-PNs, PhaseⅡ, Double-Blinded, Placebo-Controlled StudyWithdrawnNCT05825365Phase 2
- Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform NeurofibromasActive, not recruitingNCT05101148Phase 1
- A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)Active, not recruitingNCT04590235Phase 1
- Selumetinib Paediatric NF1 Japan StudyCompletedNCT04495127Phase 1
- A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade GliomaActive, not recruitingNCT03871257Phase 3
- International Trial of Selumetinib in Combination With Dexamethasone for the Treatment of Acute Lymphoblastic LeukaemiaTerminatedNCT03705507Phase 1/2
- A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerActive, not recruitingNCT03392246Phase 2
- Intermittent Dosing Of Selumetinib In Childhood NF1 Associated TumoursCompletedNCT03326388Phase 1/2
- Selumetinib and Olaparib in Solid TumorsActive, not recruitingNCT03162627Phase 1
- Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)WithdrawnNCT03109301Phase 2
- Intermittent Selumetinib for Uveal MelanomaCompletedNCT02768766Phase 1
- Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast CancerStatus unknownNCT02685657Phase 2
- National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerCompletedNCT02664935Phase 2
- A Study of AZD2014 in Combination With Selumetinib in Patients With Advanced CancersStatus unknownNCT02583542Phase 1/2
- Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
- Selumetinib and Paclitaxel as Second-Line Treatment in Treating Patients With Stage IIIB-IV Non-small Cell Lung CancerCompletedNCT02503358Phase 1
- Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerStatus unknownNCT02450656Phase 1/2
- Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line ChemotherapyCompletedNCT02448290Phase 2
- MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform NeurofibromasActive, not recruitingNCT02407405Phase 2
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerActive, not recruitingNCT02299999Phase 2
- Selumetinib and Cyclosporine in Treating Patients With Advanced Solid Tumors or Advanced or Metastatic Colorectal CancerCompletedNCT02188264Phase 1
- A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary CancerActive, not recruitingNCT02151084Phase 2
- SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC PatientsCompletedNCT02117167Phase 2
- To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male VolunteersCompletedNCT02093728Phase 1
- To Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib in Renal Impaired Subjects and Healthy SubjectsCompletedNCT02063204Phase 1
- To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male VolunteersCompletedNCT02046850Phase 1
- Selumetinib in Combination With Gefitinib in NSCLC PatientsCompletedNCT02025114Phase 1/2
- To Assess the Effect of Food on the Pharmacokinetics of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male VolunteersCompletedNCT01974349Phase 1
- Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PKCompletedNCT01960374Phase 1
- Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C] Selumetinib in VolunteersCompletedNCT01931761Phase 1
- Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By SurgeryWithdrawnNCT01859182Phase 2
- A Study of Selumetinib in Patients With Kaposi's SarcomaTerminatedNCT01752569Phase 1/2
- A Randomized, Open Label Study to Compare the Current Phase II and Planned Phase III Capsule Formulation of AZD6244CompletedNCT01635023Phase 1
- Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid MalignanciesActive, not recruitingNCT01364051Phase 1